Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Ipsen    IPN   FR0010259150

IPSEN

(IPN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Ipsen : announces sales growth over the first 9 months of 2020

10/22/2020 | 01:25am EST

Around the world, COVID-19 cases are on the rise again. Despite the challenges presented by the pandemic, our teams' commitment to delivering for patients remains as strong as ever. That's why we are especially pleased to announce our positive Q3 financial results. These results reflect both our commitment to patients and the resiliency of our portfolio. Our Q3 sales grew by 2.2% at constant exchange rates over the first nine months of 2020, despite the continuing negative impact of the COVID-19 pandemic. These results were driven by sales growth of 5.1% within our resilient Specialty Care portfolio.

We are also pleased to confirm our 2020 full-year guidance, with Group sales growth greater than +2.0% at constant currency and Core Operating margin greater than 30.0% of net sales.

Our late-stage R&D pipeline has also progressed for Cabometyx®, Somatuline® and palovarotene. We are further optimistic about growing our pipeline thanks to the recent appointment of Philippe Lopes-Fernandes as Executive Vice President, Chief Business Officer, who is charged with business development and alliance management.

'The Group delivered a resilient performance in the third quarter, despite the continued impact of the pandemic, and I am pleased to confirm our 2020 full-year financial objectives,' said David Loew, CEO. 'Our pipeline achieved notable progress with incremental positive data on Cabometyx and palovarotene, supporting our intention to bring these important therapies to patients. I look forward to sharing my long-term vision for Ipsen and the outcomes of a comprehensive strategic review at our Capital Markets Day on December 1st.'

For more information, see the press release here.

Disclaimer

Ipsen SA published this content on 22 October 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 October 2020 05:24:06 UTC


© Publicnow 2020
All news about IPSEN
11/25EACD 2020 : How the use of functional assessments in clinical trials provides me..
PU
11/18ALERT : New purchases in the Investor Europe portfolio
10/27IPSEN : Disclosure of Transactions in Own Shares Between 10/19/2020 And 10/20/20..
BU
10/23IPSEN : delivers sales growth in the first nine months of 2020 despite the impac..
AQ
10/22IPSEN : Q3 2020 Sales Conference Call – Thursday, October 22, 2020
PU
10/22IPSEN : announces sales growth over the first 9 months of 2020
PU
10/22IPSEN : delivers sales growth in the first nine months of 2020 despite the impac..
PU
10/22IPSEN : Delivers Sales Growth in the First Nine Months of 2020 Despite the Impac..
BU
10/22IPSEN : 3rd quarter results
CO
10/20IPSEN : Disclosure of Transactions in Own Shares between 10/12/2020 and 10/16/20..
BU
More news
Financials
Sales 2020 2 654 M 3 160 M 3 160 M
Net income 2020 461 M 549 M 549 M
Net Debt 2020 717 M 853 M 853 M
P/E ratio 2020 14,1x
Yield 2020 1,31%
Capitalization 6 451 M 7 683 M 7 681 M
EV / Sales 2020 2,70x
EV / Sales 2021 2,38x
Nbr of Employees 5 807
Free-Float 42,0%
Chart IPSEN
Duration : Period :
Ipsen Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IPSEN
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 96,49 €
Last Close Price 78,10 €
Spread / Highest target 44,7%
Spread / Average Target 23,5%
Spread / Lowest Target 3,71%
EPS Revisions
Managers
NameTitle
David G. Loew Chief Executive Officer & Director
Marc M. P. de Garidel Non-Executive Chairman
Aymeric Le Chatelier Chief Financial Officer & Executive Vice President
Aidan Murphy Executive Vice President-Technical Operations
Howard Mayer Executive Vice President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
IPSEN-1.14%7 683
JOHNSON & JOHNSON-1.50%378 244
ROCHE HOLDING AG-4.41%282 585
PFIZER INC.-1.59%203 048
NOVARTIS AG-11.88%202 620
MERCK & CO., INC.-11.97%202 555